The Pharmacopsychometric Triangle to Illustrate the Effectiveness of T-PEMF Concomitant with Antidepressants in Treatment Resistant Patients: A Double-Blind, Randomised, Sham-Controlled Trial Revisited with Focus on the Patient-Reported Outcomes

Table 5

The LOCF analysis with MES.

HAM-D17	Active T-PEMF	Sham T-PEMF
	(𝑁=21)	(𝑁=19)
Baseline	21.62 (3.1)	21.21 (2.7)
week 1	17.90 (5.0)**	20.00 (3.5)
week 2	16.33 (3.2)*	18.68 (4.2)
week 3	14.95 (4.0)**	18.74 (4.5)
week 4	13.05 (5.1)**	18.16 (4.8)
week 5	11.90 (5.9)**	17.79 (4.7)

* 𝑃≤.05.
** 𝑃≤.01.